nodes	percent_of_prediction	percent_of_DWPC	metapath
Nedocromil—HSP90AA1—endothelium—systemic scleroderma	0.0224	0.108	CbGeAlD
Nedocromil—FPR1—digestive system—systemic scleroderma	0.0211	0.102	CbGeAlD
Nedocromil—HSP90AA1—blood vessel—systemic scleroderma	0.0207	0.0995	CbGeAlD
Nedocromil—PTGDR—digestive system—systemic scleroderma	0.02	0.0959	CbGeAlD
Nedocromil—CYSLTR2—lung—systemic scleroderma	0.0196	0.0942	CbGeAlD
Nedocromil—HSP90AA1—Mycophenolic acid—Mycophenolate mofetil—systemic scleroderma	0.0187	1	CbGdCrCtD
Nedocromil—HSP90AA1—Integrin-linked kinase signaling—GIT2—systemic scleroderma	0.0186	0.067	CbGpPWpGaD
Nedocromil—FPR1—lung—systemic scleroderma	0.0176	0.0848	CbGeAlD
Nedocromil—PTGDR—lung—systemic scleroderma	0.0167	0.0801	CbGeAlD
Nedocromil—FPR1—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—ITGAM—systemic scleroderma	0.0162	0.0582	CbGpPWpGaD
Nedocromil—PTGDR—Prostaglandin Synthesis and Regulation—EDN1—systemic scleroderma	0.0122	0.0439	CbGpPWpGaD
Nedocromil—PTGDR—Thromboxane A2 receptor signaling—BLK—systemic scleroderma	0.0115	0.0413	CbGpPWpGaD
Nedocromil—CYSLTR1—smooth muscle tissue—systemic scleroderma	0.0112	0.0538	CbGeAlD
Nedocromil—HSP90AA1—connective tissue—systemic scleroderma	0.0106	0.051	CbGeAlD
Nedocromil—CYSLTR2—Endothelins—COL1A2—systemic scleroderma	0.00975	0.0351	CbGpPWpGaD
Nedocromil—HSP90AA1—smooth muscle tissue—systemic scleroderma	0.00971	0.0467	CbGeAlD
Nedocromil—HSP90AA1—skin of body—systemic scleroderma	0.00958	0.0461	CbGeAlD
Nedocromil—HSP90AA1—digestive system—systemic scleroderma	0.00767	0.0369	CbGeAlD
Nedocromil—HSP90AA1—eNOS activation—NOS3—systemic scleroderma	0.00759	0.0274	CbGpPWpGaD
Nedocromil—CYSLTR1—lung—systemic scleroderma	0.00738	0.0355	CbGeAlD
Nedocromil—HSP90AA1—tendon—systemic scleroderma	0.0073	0.0351	CbGeAlD
Nedocromil—HSP90AA1—Binding and Uptake of Ligands by Scavenger Receptors—COL1A2—systemic scleroderma	0.00684	0.0247	CbGpPWpGaD
Nedocromil—CYSLTR1—Endothelins—COL1A2—systemic scleroderma	0.00676	0.0244	CbGpPWpGaD
Nedocromil—HSP90AA1—lung—systemic scleroderma	0.0064	0.0308	CbGeAlD
Nedocromil—HSP90AA1—Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation—NOS3—systemic scleroderma	0.00603	0.0217	CbGpPWpGaD
Nedocromil—HSP90AA1—Class I PI3K signaling events—BLK—systemic scleroderma	0.00533	0.0192	CbGpPWpGaD
Nedocromil—HSP90AA1—Integrins in angiogenesis—CSF1—systemic scleroderma	0.00532	0.0192	CbGpPWpGaD
Nedocromil—CYSLTR2—Endothelins—EDN1—systemic scleroderma	0.00528	0.019	CbGpPWpGaD
Nedocromil—HSP90AA1—Semaphorin interactions—RHOB—systemic scleroderma	0.0049	0.0176	CbGpPWpGaD
Nedocromil—HSP90AA1—Integrins in angiogenesis—COL1A2—systemic scleroderma	0.00485	0.0175	CbGpPWpGaD
Nedocromil—HSP90AA1—Regulation of actin dynamics for phagocytic cup formation—CD247—systemic scleroderma	0.00477	0.0172	CbGpPWpGaD
Nedocromil—FPR1—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—MMP9—systemic scleroderma	0.00471	0.017	CbGpPWpGaD
Nedocromil—PTGDR—Thromboxane A2 receptor signaling—NOS3—systemic scleroderma	0.0045	0.0162	CbGpPWpGaD
Nedocromil—CYSLTR2—Endothelins—MMP1—systemic scleroderma	0.00444	0.016	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism of nitric oxide—NOS3—systemic scleroderma	0.00418	0.015	CbGpPWpGaD
Nedocromil—FPR1—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—TGFB1—systemic scleroderma	0.00388	0.014	CbGpPWpGaD
Nedocromil—CYSLTR1—Endothelins—EDN1—systemic scleroderma	0.00366	0.0132	CbGpPWpGaD
Nedocromil—HSP90AA1—Fcgamma receptor (FCGR) dependent phagocytosis—CD247—systemic scleroderma	0.0036	0.013	CbGpPWpGaD
Nedocromil—HSP90AA1—Glucocorticoid receptor regulatory network—IL13—systemic scleroderma	0.00336	0.0121	CbGpPWpGaD
Nedocromil—CYSLTR1—Endothelins—MMP1—systemic scleroderma	0.00308	0.0111	CbGpPWpGaD
Nedocromil—HSP90AA1—VEGFR2 mediated vascular permeability—NOS3—systemic scleroderma	0.00306	0.011	CbGpPWpGaD
Nedocromil—HSP90AA1—TNF alpha Signaling Pathway—TNFAIP3—systemic scleroderma	0.00305	0.011	CbGpPWpGaD
Nedocromil—HSP90AA1—VEGFR1 specific signals—NOS3—systemic scleroderma	0.00298	0.0107	CbGpPWpGaD
Nedocromil—FPR1—Peptide ligand-binding receptors—EDN1—systemic scleroderma	0.00288	0.0104	CbGpPWpGaD
Nedocromil—Tremor—Pentoxifylline—systemic scleroderma	0.00222	0.00448	CcSEcCtD
Nedocromil—CYSLTR2—G alpha (q) signalling events—EDN1—systemic scleroderma	0.00221	0.00797	CbGpPWpGaD
Nedocromil—Arthritis—Lisinopril—systemic scleroderma	0.00218	0.00439	CcSEcCtD
Nedocromil—Ear pain—Mycophenolate mofetil—systemic scleroderma	0.00217	0.00438	CcSEcCtD
Nedocromil—Influenza—Leflunomide—systemic scleroderma	0.00213	0.00429	CcSEcCtD
Nedocromil—Leukopenia—Pentoxifylline—systemic scleroderma	0.00212	0.00428	CcSEcCtD
Nedocromil—Eosinophilia—Leflunomide—systemic scleroderma	0.00211	0.00425	CcSEcCtD
Nedocromil—Gastroenteritis—Mycophenolate mofetil—systemic scleroderma	0.00209	0.00422	CcSEcCtD
Nedocromil—Rhinitis—Captopril—systemic scleroderma	0.00207	0.00418	CcSEcCtD
Nedocromil—Pharyngitis—Captopril—systemic scleroderma	0.00205	0.00413	CcSEcCtD
Nedocromil—Bronchitis—Leflunomide—systemic scleroderma	0.00205	0.00413	CcSEcCtD
Nedocromil—Influenza—Mycophenolic acid—systemic scleroderma	0.00203	0.00409	CcSEcCtD
Nedocromil—Chest pain—Pentoxifylline—systemic scleroderma	0.00202	0.00407	CcSEcCtD
Nedocromil—Pneumonia—Azathioprine—systemic scleroderma	0.00202	0.00407	CcSEcCtD
Nedocromil—HSP90AA1—Signaling by EGFR in Cancer—CSK—systemic scleroderma	0.00201	0.00726	CbGpPWpGaD
Nedocromil—CYSLTR2—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—systemic scleroderma	0.00198	0.00713	CbGpPWpGaD
Nedocromil—Upper respiratory tract infection—Leflunomide—systemic scleroderma	0.00198	0.00399	CcSEcCtD
Nedocromil—Dry mouth—Pentoxifylline—systemic scleroderma	0.00198	0.00398	CcSEcCtD
Nedocromil—FPR1—Peptide ligand-binding receptors—CCL2—systemic scleroderma	0.00197	0.0071	CbGpPWpGaD
Nedocromil—Bronchitis—Mycophenolic acid—systemic scleroderma	0.00195	0.00394	CcSEcCtD
Nedocromil—Anaphylactic shock—Pentoxifylline—systemic scleroderma	0.00194	0.00391	CcSEcCtD
Nedocromil—FPR1—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.00193	0.00696	CbGpPWpGaD
Nedocromil—HSP90AA1—NOD pathway—IL1B—systemic scleroderma	0.00192	0.00692	CbGpPWpGaD
Nedocromil—Viral infection—Prednisone—systemic scleroderma	0.00192	0.00386	CcSEcCtD
Nedocromil—Pneumonia—Leflunomide—systemic scleroderma	0.00191	0.00385	CcSEcCtD
Nedocromil—Upper respiratory tract infection—Mycophenolic acid—systemic scleroderma	0.00189	0.0038	CcSEcCtD
Nedocromil—PTGDR—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.00187	0.00672	CbGpPWpGaD
Nedocromil—Conjunctivitis—Leflunomide—systemic scleroderma	0.00184	0.00372	CcSEcCtD
Nedocromil—Influenza—Lisinopril—systemic scleroderma	0.00183	0.00369	CcSEcCtD
Nedocromil—HSP90AA1—Cell Cycle, Mitotic—CENPC—systemic scleroderma	0.00182	0.00658	CbGpPWpGaD
Nedocromil—Pneumonia—Mycophenolic acid—systemic scleroderma	0.00182	0.00367	CcSEcCtD
Nedocromil—Eosinophilia—Lisinopril—systemic scleroderma	0.00181	0.00365	CcSEcCtD
Nedocromil—HSP90AA1—Glucocorticoid receptor regulatory network—MMP1—systemic scleroderma	0.00179	0.00644	CbGpPWpGaD
Nedocromil—Cough—Mometasone—systemic scleroderma	0.00179	0.0036	CcSEcCtD
Nedocromil—Sinusitis—Leflunomide—systemic scleroderma	0.00178	0.00359	CcSEcCtD
Nedocromil—Dysgeusia—Captopril—systemic scleroderma	0.00176	0.00355	CcSEcCtD
Nedocromil—Conjunctivitis—Mycophenolic acid—systemic scleroderma	0.00176	0.00355	CcSEcCtD
Nedocromil—Bronchitis—Lisinopril—systemic scleroderma	0.00176	0.00354	CcSEcCtD
Nedocromil—HSP90AA1—Aryl Hydrocarbon Receptor Pathway—IL1B—systemic scleroderma	0.00175	0.00631	CbGpPWpGaD
Nedocromil—Chest pain—Mometasone—systemic scleroderma	0.00174	0.00352	CcSEcCtD
Nedocromil—Dyspnoea—Pentoxifylline—systemic scleroderma	0.00173	0.00348	CcSEcCtD
Nedocromil—Rhinitis—Leflunomide—systemic scleroderma	0.00171	0.00344	CcSEcCtD
Nedocromil—Dry mouth—Mometasone—systemic scleroderma	0.0017	0.00344	CcSEcCtD
Nedocromil—Dyspepsia—Pentoxifylline—systemic scleroderma	0.0017	0.00344	CcSEcCtD
Nedocromil—Upper respiratory tract infection—Lisinopril—systemic scleroderma	0.0017	0.00343	CcSEcCtD
Nedocromil—Sinusitis—Mycophenolic acid—systemic scleroderma	0.0017	0.00342	CcSEcCtD
Nedocromil—Pharyngitis—Leflunomide—systemic scleroderma	0.00169	0.00341	CcSEcCtD
Nedocromil—Anaphylactic shock—Mometasone—systemic scleroderma	0.00167	0.00337	CcSEcCtD
Nedocromil—Pneumonia—Lisinopril—systemic scleroderma	0.00164	0.00331	CcSEcCtD
Nedocromil—HSP90AA1—Cell Cycle—CENPC—systemic scleroderma	0.00163	0.00588	CbGpPWpGaD
Nedocromil—FPR1—GPCR downstream signaling—RHOB—systemic scleroderma	0.00163	0.00587	CbGpPWpGaD
Nedocromil—Rhinitis—Mycophenolic acid—systemic scleroderma	0.00163	0.00328	CcSEcCtD
Nedocromil—Pharyngitis—Mycophenolic acid—systemic scleroderma	0.00161	0.00325	CcSEcCtD
Nedocromil—Influenza—Mycophenolate mofetil—systemic scleroderma	0.0016	0.00323	CcSEcCtD
Nedocromil—Gastrointestinal pain—Pentoxifylline—systemic scleroderma	0.00158	0.00319	CcSEcCtD
Nedocromil—PTGDR—GPCR downstream signaling—RHOB—systemic scleroderma	0.00157	0.00567	CbGpPWpGaD
Nedocromil—Cough—Captopril—systemic scleroderma	0.00157	0.00316	CcSEcCtD
Nedocromil—Visual impairment—Mycophenolic acid—systemic scleroderma	0.00157	0.00316	CcSEcCtD
Nedocromil—Bronchitis—Mycophenolate mofetil—systemic scleroderma	0.00154	0.00311	CcSEcCtD
Nedocromil—Urticaria—Pentoxifylline—systemic scleroderma	0.00154	0.0031	CcSEcCtD
Nedocromil—CYSLTR1—G alpha (q) signalling events—EDN1—systemic scleroderma	0.00153	0.00552	CbGpPWpGaD
Nedocromil—Chest pain—Captopril—systemic scleroderma	0.00153	0.00309	CcSEcCtD
Nedocromil—Body temperature increased—Pentoxifylline—systemic scleroderma	0.00153	0.00309	CcSEcCtD
Nedocromil—Abdominal pain—Pentoxifylline—systemic scleroderma	0.00153	0.00309	CcSEcCtD
Nedocromil—Sinusitis—Lisinopril—systemic scleroderma	0.00153	0.00308	CcSEcCtD
Nedocromil—HSP90AA1—Signaling events mediated by VEGFR1 and VEGFR2—NOS3—systemic scleroderma	0.00151	0.00543	CbGpPWpGaD
Nedocromil—Dry mouth—Captopril—systemic scleroderma	0.0015	0.00302	CcSEcCtD
Nedocromil—Dyspnoea—Mometasone—systemic scleroderma	0.00149	0.003	CcSEcCtD
Nedocromil—FPR1—Signaling by GPCR—RHOB—systemic scleroderma	0.00148	0.00533	CbGpPWpGaD
Nedocromil—FPR1—GPCR ligand binding—EDN1—systemic scleroderma	0.00147	0.0053	CbGpPWpGaD
Nedocromil—Dyspepsia—Mometasone—systemic scleroderma	0.00147	0.00297	CcSEcCtD
Nedocromil—Anaphylactic shock—Captopril—systemic scleroderma	0.00147	0.00296	CcSEcCtD
Nedocromil—Rhinitis—Lisinopril—systemic scleroderma	0.00147	0.00296	CcSEcCtD
Nedocromil—CYSLTR2—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.00146	0.00528	CbGpPWpGaD
Nedocromil—Pharyngitis—Lisinopril—systemic scleroderma	0.00145	0.00293	CcSEcCtD
Nedocromil—Dysgeusia—Leflunomide—systemic scleroderma	0.00145	0.00293	CcSEcCtD
Nedocromil—Fatigue—Mometasone—systemic scleroderma	0.00144	0.00291	CcSEcCtD
Nedocromil—Pneumonia—Mycophenolate mofetil—systemic scleroderma	0.00144	0.0029	CcSEcCtD
Nedocromil—Pain—Mometasone—systemic scleroderma	0.00143	0.00288	CcSEcCtD
Nedocromil—PTGDR—Signaling by GPCR—RHOB—systemic scleroderma	0.00143	0.00515	CbGpPWpGaD
Nedocromil—Hypersensitivity—Pentoxifylline—systemic scleroderma	0.00143	0.00288	CcSEcCtD
Nedocromil—PTGDR—GPCR ligand binding—EDN1—systemic scleroderma	0.00142	0.00512	CbGpPWpGaD
Nedocromil—Leukopenia—Azathioprine—systemic scleroderma	0.0014	0.00283	CcSEcCtD
Nedocromil—Asthenia—Pentoxifylline—systemic scleroderma	0.00139	0.0028	CcSEcCtD
Nedocromil—HSP90AA1—Axon guidance—RHOB—systemic scleroderma	0.00139	0.005	CbGpPWpGaD
Nedocromil—Conjunctivitis—Mycophenolate mofetil—systemic scleroderma	0.00139	0.0028	CcSEcCtD
Nedocromil—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—systemic scleroderma	0.00137	0.00494	CbGpPWpGaD
Nedocromil—Gastrointestinal pain—Mometasone—systemic scleroderma	0.00137	0.00276	CcSEcCtD
Nedocromil—HSP90AA1—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	0.00136	0.0049	CbGpPWpGaD
Nedocromil—Sinusitis—Mycophenolate mofetil—systemic scleroderma	0.00134	0.0027	CcSEcCtD
Nedocromil—Leukopenia—Leflunomide—systemic scleroderma	0.00133	0.00268	CcSEcCtD
Nedocromil—HSP90AA1—TNF alpha Signaling Pathway—CCL2—systemic scleroderma	0.00133	0.00478	CbGpPWpGaD
Nedocromil—Diarrhoea—Pentoxifylline—systemic scleroderma	0.00132	0.00267	CcSEcCtD
Nedocromil—Tremor—Mycophenolic acid—systemic scleroderma	0.00132	0.00267	CcSEcCtD
Nedocromil—Abdominal pain—Mometasone—systemic scleroderma	0.00132	0.00266	CcSEcCtD
Nedocromil—Body temperature increased—Mometasone—systemic scleroderma	0.00132	0.00266	CcSEcCtD
Nedocromil—FPR1—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.00132	0.00476	CbGpPWpGaD
Nedocromil—Dyspnoea—Captopril—systemic scleroderma	0.00131	0.00264	CcSEcCtD
Nedocromil—Cough—Leflunomide—systemic scleroderma	0.00129	0.00261	CcSEcCtD
Nedocromil—Dyspepsia—Captopril—systemic scleroderma	0.00129	0.00261	CcSEcCtD
Nedocromil—Rhinitis—Mycophenolate mofetil—systemic scleroderma	0.00128	0.00259	CcSEcCtD
Nedocromil—Dizziness—Pentoxifylline—systemic scleroderma	0.00128	0.00258	CcSEcCtD
Nedocromil—PTGDR—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.00128	0.0046	CbGpPWpGaD
Nedocromil—Pharyngitis—Mycophenolate mofetil—systemic scleroderma	0.00127	0.00257	CcSEcCtD
Nedocromil—Leukopenia—Mycophenolic acid—systemic scleroderma	0.00127	0.00255	CcSEcCtD
Nedocromil—Fatigue—Captopril—systemic scleroderma	0.00127	0.00255	CcSEcCtD
Nedocromil—Chest pain—Leflunomide—systemic scleroderma	0.00126	0.00254	CcSEcCtD
Nedocromil—Dysgeusia—Lisinopril—systemic scleroderma	0.00125	0.00252	CcSEcCtD
Nedocromil—HSP90AA1—EPH-Ephrin signaling—MMP2—systemic scleroderma	0.00124	0.00447	CbGpPWpGaD
Nedocromil—Visual impairment—Mycophenolate mofetil—systemic scleroderma	0.00124	0.00249	CcSEcCtD
Nedocromil—CYSLTR2—GPCR downstream signaling—RHOB—systemic scleroderma	0.00123	0.00445	CbGpPWpGaD
Nedocromil—Dry mouth—Leflunomide—systemic scleroderma	0.00123	0.00249	CcSEcCtD
Nedocromil—Cough—Mycophenolic acid—systemic scleroderma	0.00123	0.00249	CcSEcCtD
Nedocromil—Vomiting—Pentoxifylline—systemic scleroderma	0.00123	0.00248	CcSEcCtD
Nedocromil—Rash—Pentoxifylline—systemic scleroderma	0.00122	0.00246	CcSEcCtD
Nedocromil—Dermatitis—Pentoxifylline—systemic scleroderma	0.00122	0.00246	CcSEcCtD
Nedocromil—Headache—Pentoxifylline—systemic scleroderma	0.00121	0.00245	CcSEcCtD
Nedocromil—Anaphylactic shock—Leflunomide—systemic scleroderma	0.00121	0.00244	CcSEcCtD
Nedocromil—Chest pain—Mycophenolic acid—systemic scleroderma	0.0012	0.00243	CcSEcCtD
Nedocromil—Gastrointestinal pain—Captopril—systemic scleroderma	0.0012	0.00242	CcSEcCtD
Nedocromil—Asthenia—Mometasone—systemic scleroderma	0.0012	0.00242	CcSEcCtD
Nedocromil—Tremor—Lisinopril—systemic scleroderma	0.00119	0.00241	CcSEcCtD
Nedocromil—HSP90AA1—Corticotropin-releasing hormone—NOS3—systemic scleroderma	0.00118	0.00426	CbGpPWpGaD
Nedocromil—Dry mouth—Mycophenolic acid—systemic scleroderma	0.00118	0.00237	CcSEcCtD
Nedocromil—Body temperature increased—Captopril—systemic scleroderma	0.00116	0.00234	CcSEcCtD
Nedocromil—Abdominal pain—Captopril—systemic scleroderma	0.00116	0.00234	CcSEcCtD
Nedocromil—HSP90AA1—Cell Cycle, Mitotic—CENPA—systemic scleroderma	0.00116	0.00418	CbGpPWpGaD
Nedocromil—Nausea—Pentoxifylline—systemic scleroderma	0.00115	0.00232	CcSEcCtD
Nedocromil—Diarrhoea—Mometasone—systemic scleroderma	0.00114	0.00231	CcSEcCtD
Nedocromil—Leukopenia—Lisinopril—systemic scleroderma	0.00114	0.0023	CcSEcCtD
Nedocromil—FPR1—Signaling Pathways—SMAD7—systemic scleroderma	0.00113	0.00407	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—RHOB—systemic scleroderma	0.00112	0.00404	CbGpPWpGaD
Nedocromil—CYSLTR2—GPCR ligand binding—EDN1—systemic scleroderma	0.00111	0.00402	CbGpPWpGaD
Nedocromil—Cough—Lisinopril—systemic scleroderma	0.00111	0.00224	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.00111	0.00223	CcSEcCtD
Nedocromil—Dysgeusia—Mycophenolate mofetil—systemic scleroderma	0.00109	0.0022	CcSEcCtD
Nedocromil—PTGDR—Signaling Pathways—SMAD7—systemic scleroderma	0.00109	0.00393	CbGpPWpGaD
Nedocromil—Chest pain—Lisinopril—systemic scleroderma	0.00108	0.00219	CcSEcCtD
Nedocromil—Dyspnoea—Leflunomide—systemic scleroderma	0.00108	0.00217	CcSEcCtD
Nedocromil—HSP90AA1—Validated targets of C-MYC transcriptional activation—MMP9—systemic scleroderma	0.00107	0.00386	CbGpPWpGaD
Nedocromil—Dyspepsia—Leflunomide—systemic scleroderma	0.00106	0.00215	CcSEcCtD
Nedocromil—Vomiting—Mometasone—systemic scleroderma	0.00106	0.00214	CcSEcCtD
Nedocromil—Dry mouth—Lisinopril—systemic scleroderma	0.00106	0.00214	CcSEcCtD
Nedocromil—Rash—Mometasone—systemic scleroderma	0.00105	0.00212	CcSEcCtD
Nedocromil—Asthenia—Captopril—systemic scleroderma	0.00105	0.00212	CcSEcCtD
Nedocromil—Dermatitis—Mometasone—systemic scleroderma	0.00105	0.00212	CcSEcCtD
Nedocromil—HSP90AA1—VEGFA-VEGFR2 Pathway—NOS3—systemic scleroderma	0.00105	0.00378	CbGpPWpGaD
Nedocromil—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.00105	0.00211	CcSEcCtD
Nedocromil—Headache—Mometasone—systemic scleroderma	0.00105	0.00211	CcSEcCtD
Nedocromil—Tremor—Mycophenolate mofetil—systemic scleroderma	0.00105	0.00211	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.00104	0.00211	CcSEcCtD
Nedocromil—Fatigue—Leflunomide—systemic scleroderma	0.00104	0.0021	CcSEcCtD
Nedocromil—Anaphylactic shock—Lisinopril—systemic scleroderma	0.00104	0.0021	CcSEcCtD
Nedocromil—HSP90AA1—Cell Cycle—CENPA—systemic scleroderma	0.00104	0.00373	CbGpPWpGaD
Nedocromil—Pain—Leflunomide—systemic scleroderma	0.00103	0.00209	CcSEcCtD
Nedocromil—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.00103	0.00207	CcSEcCtD
Nedocromil—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.00102	0.00205	CcSEcCtD
Nedocromil—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.00101	0.00366	CbGpPWpGaD
Nedocromil—Abdominal pain—Azathioprine—systemic scleroderma	0.00101	0.00204	CcSEcCtD
Nedocromil—Body temperature increased—Azathioprine—systemic scleroderma	0.00101	0.00204	CcSEcCtD
Nedocromil—FPR1—GPCR ligand binding—CCL2—systemic scleroderma	0.00101	0.00362	CbGpPWpGaD
Nedocromil—Diarrhoea—Captopril—systemic scleroderma	0.001	0.00203	CcSEcCtD
Nedocromil—CYSLTR2—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.001	0.00361	CbGpPWpGaD
Nedocromil—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000999	0.00201	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000996	0.00201	CcSEcCtD
Nedocromil—HSP90AA1—Regulation of Telomerase—TGFB1—systemic scleroderma	0.000995	0.00359	CbGpPWpGaD
Nedocromil—Fatigue—Mycophenolic acid—systemic scleroderma	0.000995	0.00201	CcSEcCtD
Nedocromil—Nausea—Mometasone—systemic scleroderma	0.000992	0.002	CcSEcCtD
Nedocromil—HSP90AA1—Developmental Biology—RHOB—systemic scleroderma	0.00099	0.00357	CbGpPWpGaD
Nedocromil—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000989	0.00199	CcSEcCtD
Nedocromil—HSP90AA1—Signaling by VEGF—NOS3—systemic scleroderma	0.000989	0.00356	CbGpPWpGaD
Nedocromil—Pain—Mycophenolic acid—systemic scleroderma	0.000987	0.00199	CcSEcCtD
Nedocromil—Cough—Mycophenolate mofetil—systemic scleroderma	0.000974	0.00196	CcSEcCtD
Nedocromil—PTGDR—GPCR ligand binding—CCL2—systemic scleroderma	0.000971	0.0035	CbGpPWpGaD
Nedocromil—Dizziness—Captopril—systemic scleroderma	0.00097	0.00196	CcSEcCtD
Nedocromil—Urticaria—Leflunomide—systemic scleroderma	0.000961	0.00194	CcSEcCtD
Nedocromil—Body temperature increased—Leflunomide—systemic scleroderma	0.000956	0.00193	CcSEcCtD
Nedocromil—Abdominal pain—Leflunomide—systemic scleroderma	0.000956	0.00193	CcSEcCtD
Nedocromil—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.00095	0.00192	CcSEcCtD
Nedocromil—Hypersensitivity—Azathioprine—systemic scleroderma	0.000944	0.0019	CcSEcCtD
Nedocromil—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000944	0.0019	CcSEcCtD
Nedocromil—Vomiting—Captopril—systemic scleroderma	0.000933	0.00188	CcSEcCtD
Nedocromil—HSP90AA1—EPH-Ephrin signaling—MMP9—systemic scleroderma	0.000932	0.00336	CbGpPWpGaD
Nedocromil—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000929	0.00187	CcSEcCtD
Nedocromil—Dyspnoea—Lisinopril—systemic scleroderma	0.000927	0.00187	CcSEcCtD
Nedocromil—Rash—Captopril—systemic scleroderma	0.000925	0.00187	CcSEcCtD
Nedocromil—Dermatitis—Captopril—systemic scleroderma	0.000924	0.00186	CcSEcCtD
Nedocromil—Headache—Captopril—systemic scleroderma	0.000919	0.00185	CcSEcCtD
Nedocromil—Dyspepsia—Lisinopril—systemic scleroderma	0.000915	0.00185	CcSEcCtD
Nedocromil—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000912	0.00184	CcSEcCtD
Nedocromil—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000912	0.00184	CcSEcCtD
Nedocromil—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000911	0.00184	CcSEcCtD
Nedocromil—Eosinophilia—Methotrexate—systemic scleroderma	0.000898	0.00181	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000897	0.00181	CcSEcCtD
Nedocromil—Fatigue—Lisinopril—systemic scleroderma	0.000896	0.00181	CcSEcCtD
Nedocromil—Hypersensitivity—Leflunomide—systemic scleroderma	0.000891	0.0018	CcSEcCtD
Nedocromil—Pain—Lisinopril—systemic scleroderma	0.000889	0.00179	CcSEcCtD
Nedocromil—Diarrhoea—Azathioprine—systemic scleroderma	0.000876	0.00177	CcSEcCtD
Nedocromil—FPR1—Signaling Pathways—RHOB—systemic scleroderma	0.000874	0.00315	CbGpPWpGaD
Nedocromil—Nausea—Captopril—systemic scleroderma	0.000872	0.00176	CcSEcCtD
Nedocromil—Asthenia—Leflunomide—systemic scleroderma	0.000868	0.00175	CcSEcCtD
Nedocromil—CYSLTR2—Signaling Pathways—SMAD7—systemic scleroderma	0.000856	0.00308	CbGpPWpGaD
Nedocromil—CYSLTR1—GPCR downstream signaling—RHOB—systemic scleroderma	0.000855	0.00308	CbGpPWpGaD
Nedocromil—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.00085	0.00171	CcSEcCtD
Nedocromil—Dizziness—Azathioprine—systemic scleroderma	0.000847	0.00171	CcSEcCtD
Nedocromil—PTGDR—Signaling Pathways—RHOB—systemic scleroderma	0.000844	0.00304	CbGpPWpGaD
Nedocromil—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000843	0.0017	CcSEcCtD
Nedocromil—FPR1—GPCR downstream signaling—EDN1—systemic scleroderma	0.000831	0.003	CbGpPWpGaD
Nedocromil—HSP90AA1—Cellular responses to stress—IL1A—systemic scleroderma	0.00083	0.00299	CbGpPWpGaD
Nedocromil—Asthenia—Mycophenolic acid—systemic scleroderma	0.000828	0.00167	CcSEcCtD
Nedocromil—Diarrhoea—Leflunomide—systemic scleroderma	0.000828	0.00167	CcSEcCtD
Nedocromil—Urticaria—Lisinopril—systemic scleroderma	0.000826	0.00167	CcSEcCtD
Nedocromil—FPR1—Signaling Pathways—HSPG2—systemic scleroderma	0.000824	0.00297	CbGpPWpGaD
Nedocromil—Abdominal pain—Lisinopril—systemic scleroderma	0.000822	0.00166	CcSEcCtD
Nedocromil—Body temperature increased—Lisinopril—systemic scleroderma	0.000822	0.00166	CcSEcCtD
Nedocromil—Vomiting—Azathioprine—systemic scleroderma	0.000814	0.00164	CcSEcCtD
Nedocromil—Pneumonia—Methotrexate—systemic scleroderma	0.000814	0.00164	CcSEcCtD
Nedocromil—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000812	0.00164	CcSEcCtD
Nedocromil—Rash—Azathioprine—systemic scleroderma	0.000808	0.00163	CcSEcCtD
Nedocromil—Dermatitis—Azathioprine—systemic scleroderma	0.000807	0.00163	CcSEcCtD
Nedocromil—PTGDR—GPCR downstream signaling—EDN1—systemic scleroderma	0.000803	0.00289	CbGpPWpGaD
Nedocromil—Headache—Azathioprine—systemic scleroderma	0.000802	0.00162	CcSEcCtD
Nedocromil—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000802	0.00162	CcSEcCtD
Nedocromil—Dizziness—Leflunomide—systemic scleroderma	0.0008	0.00161	CcSEcCtD
Nedocromil—PTGDR—Signaling Pathways—HSPG2—systemic scleroderma	0.000796	0.00287	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—CSK—systemic scleroderma	0.000796	0.00287	CbGpPWpGaD
Nedocromil—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000789	0.00159	CcSEcCtD
Nedocromil—Conjunctivitis—Methotrexate—systemic scleroderma	0.000786	0.00159	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000786	0.00159	CcSEcCtD
Nedocromil—HSP90AA1—Corticotropin-releasing hormone—TGFB1—systemic scleroderma	0.000782	0.00282	CbGpPWpGaD
Nedocromil—Pain—Mycophenolate mofetil—systemic scleroderma	0.000779	0.00157	CcSEcCtD
Nedocromil—CYSLTR1—Signaling by GPCR—RHOB—systemic scleroderma	0.000777	0.0028	CbGpPWpGaD
Nedocromil—CYSLTR1—GPCR ligand binding—EDN1—systemic scleroderma	0.000773	0.00279	CbGpPWpGaD
Nedocromil—Vomiting—Leflunomide—systemic scleroderma	0.000769	0.00155	CcSEcCtD
Nedocromil—PTGDR—Signaling Pathways—CSK—systemic scleroderma	0.000768	0.00277	CbGpPWpGaD
Nedocromil—Hypersensitivity—Lisinopril—systemic scleroderma	0.000766	0.00154	CcSEcCtD
Nedocromil—Dizziness—Mycophenolic acid—systemic scleroderma	0.000763	0.00154	CcSEcCtD
Nedocromil—Rash—Leflunomide—systemic scleroderma	0.000763	0.00154	CcSEcCtD
Nedocromil—CYSLTR2—GPCR ligand binding—CCL2—systemic scleroderma	0.000762	0.00275	CbGpPWpGaD
Nedocromil—Dermatitis—Leflunomide—systemic scleroderma	0.000762	0.00154	CcSEcCtD
Nedocromil—Nausea—Azathioprine—systemic scleroderma	0.000761	0.00153	CcSEcCtD
Nedocromil—Headache—Leflunomide—systemic scleroderma	0.000758	0.00153	CcSEcCtD
Nedocromil—FPR1—Signaling by GPCR—EDN1—systemic scleroderma	0.000755	0.00272	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—CD247—systemic scleroderma	0.000749	0.0027	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—ITGAM—systemic scleroderma	0.000749	0.0027	CbGpPWpGaD
Nedocromil—Asthenia—Lisinopril—systemic scleroderma	0.000746	0.0015	CcSEcCtD
Nedocromil—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000745	0.0015	CcSEcCtD
Nedocromil—Vomiting—Mycophenolic acid—systemic scleroderma	0.000734	0.00148	CcSEcCtD
Nedocromil—PTGDR—Signaling by GPCR—EDN1—systemic scleroderma	0.000729	0.00263	CbGpPWpGaD
Nedocromil—Rash—Mycophenolic acid—systemic scleroderma	0.000728	0.00147	CcSEcCtD
Nedocromil—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000727	0.00147	CcSEcCtD
Nedocromil—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000723	0.00146	CcSEcCtD
Nedocromil—Headache—Mycophenolic acid—systemic scleroderma	0.000723	0.00146	CcSEcCtD
Nedocromil—Pharyngitis—Methotrexate—systemic scleroderma	0.000721	0.00145	CcSEcCtD
Nedocromil—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.00072	0.00145	CcSEcCtD
Nedocromil—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.00072	0.00145	CcSEcCtD
Nedocromil—Nausea—Leflunomide—systemic scleroderma	0.000718	0.00145	CcSEcCtD
Nedocromil—Diarrhoea—Lisinopril—systemic scleroderma	0.000711	0.00143	CcSEcCtD
Nedocromil—HSP90AA1—Innate Immune System—TNFAIP3—systemic scleroderma	0.000701	0.00253	CbGpPWpGaD
Nedocromil—Visual impairment—Methotrexate—systemic scleroderma	0.0007	0.00141	CcSEcCtD
Nedocromil—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.000694	0.0025	CbGpPWpGaD
Nedocromil—Dizziness—Lisinopril—systemic scleroderma	0.000687	0.00139	CcSEcCtD
Nedocromil—Nausea—Mycophenolic acid—systemic scleroderma	0.000685	0.00138	CcSEcCtD
Nedocromil—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000671	0.00135	CcSEcCtD
Nedocromil—CYSLTR2—Signaling Pathways—RHOB—systemic scleroderma	0.000662	0.00239	CbGpPWpGaD
Nedocromil—Vomiting—Lisinopril—systemic scleroderma	0.000661	0.00133	CcSEcCtD
Nedocromil—Rash—Lisinopril—systemic scleroderma	0.000655	0.00132	CcSEcCtD
Nedocromil—Dermatitis—Lisinopril—systemic scleroderma	0.000655	0.00132	CcSEcCtD
Nedocromil—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000653	0.00132	CcSEcCtD
Nedocromil—Headache—Lisinopril—systemic scleroderma	0.000651	0.00131	CcSEcCtD
Nedocromil—CYSLTR2—GPCR downstream signaling—EDN1—systemic scleroderma	0.00063	0.00227	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—HSPG2—systemic scleroderma	0.000624	0.00225	CbGpPWpGaD
Nedocromil—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000623	0.00126	CcSEcCtD
Nedocromil—Dysgeusia—Methotrexate—systemic scleroderma	0.000619	0.00125	CcSEcCtD
Nedocromil—Nausea—Lisinopril—systemic scleroderma	0.000617	0.00125	CcSEcCtD
Nedocromil—Anaphylactic shock—Prednisone—systemic scleroderma	0.000617	0.00124	CcSEcCtD
Nedocromil—HSP90AA1—Disease—SMAD7—systemic scleroderma	0.000608	0.00219	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CSK—systemic scleroderma	0.000603	0.00217	CbGpPWpGaD
Nedocromil—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000602	0.00121	CcSEcCtD
Nedocromil—CYSLTR1—Signaling Pathways—SMAD7—systemic scleroderma	0.000593	0.00214	CbGpPWpGaD
Nedocromil—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000579	0.00117	CcSEcCtD
Nedocromil—Rash—Mycophenolate mofetil—systemic scleroderma	0.000574	0.00116	CcSEcCtD
Nedocromil—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000574	0.00116	CcSEcCtD
Nedocromil—CYSLTR2—Signaling by GPCR—EDN1—systemic scleroderma	0.000572	0.00206	CbGpPWpGaD
Nedocromil—Headache—Mycophenolate mofetil—systemic scleroderma	0.00057	0.00115	CcSEcCtD
Nedocromil—Leukopenia—Methotrexate—systemic scleroderma	0.000566	0.00114	CcSEcCtD
Nedocromil—HSP90AA1—Disease—TGFBI—systemic scleroderma	0.000556	0.002	CbGpPWpGaD
Nedocromil—HSP90AA1—Influenza Infection—TGFB1—systemic scleroderma	0.000555	0.002	CbGpPWpGaD
Nedocromil—Cough—Methotrexate—systemic scleroderma	0.000552	0.00111	CcSEcCtD
Nedocromil—Dyspepsia—Prednisone—systemic scleroderma	0.000543	0.0011	CcSEcCtD
Nedocromil—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000541	0.00109	CcSEcCtD
Nedocromil—HSP90AA1—NRF2 pathway—TGFB1—systemic scleroderma	0.00054	0.00195	CbGpPWpGaD
Nedocromil—Chest pain—Methotrexate—systemic scleroderma	0.000538	0.00109	CcSEcCtD
Nedocromil—Fatigue—Prednisone—systemic scleroderma	0.000532	0.00107	CcSEcCtD
Nedocromil—CYSLTR1—GPCR ligand binding—CCL2—systemic scleroderma	0.000528	0.0019	CbGpPWpGaD
Nedocromil—FPR1—Signaling by GPCR—CCL2—systemic scleroderma	0.000516	0.00186	CbGpPWpGaD
Nedocromil—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000516	0.00104	CcSEcCtD
Nedocromil—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000505	0.00102	CcSEcCtD
Nedocromil—PTGDR—Signaling by GPCR—CCL2—systemic scleroderma	0.000498	0.0018	CbGpPWpGaD
Nedocromil—Urticaria—Prednisone—systemic scleroderma	0.00049	0.000989	CcSEcCtD
Nedocromil—Abdominal pain—Prednisone—systemic scleroderma	0.000488	0.000984	CcSEcCtD
Nedocromil—Body temperature increased—Prednisone—systemic scleroderma	0.000488	0.000984	CcSEcCtD
Nedocromil—HSP90AA1—Immune System—CSK—systemic scleroderma	0.000464	0.00167	CbGpPWpGaD
Nedocromil—HSP90AA1—Axon guidance—MMP2—systemic scleroderma	0.000461	0.00166	CbGpPWpGaD
Nedocromil—Dyspnoea—Methotrexate—systemic scleroderma	0.00046	0.000928	CcSEcCtD
Nedocromil—CYSLTR1—Signaling Pathways—RHOB—systemic scleroderma	0.000459	0.00165	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—IRF5—systemic scleroderma	0.000456	0.00165	CbGpPWpGaD
Nedocromil—Hypersensitivity—Prednisone—systemic scleroderma	0.000455	0.000917	CcSEcCtD
Nedocromil—Dyspepsia—Methotrexate—systemic scleroderma	0.000454	0.000916	CcSEcCtD
Nedocromil—FPR1—Signaling Pathways—EDN1—systemic scleroderma	0.000446	0.00161	CbGpPWpGaD
Nedocromil—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000445	0.000898	CcSEcCtD
Nedocromil—Fatigue—Methotrexate—systemic scleroderma	0.000445	0.000897	CcSEcCtD
Nedocromil—HSP90AA1—Disease—HSPG2—systemic scleroderma	0.000444	0.0016	CbGpPWpGaD
Nedocromil—Asthenia—Prednisone—systemic scleroderma	0.000443	0.000893	CcSEcCtD
Nedocromil—Pain—Methotrexate—systemic scleroderma	0.000441	0.00089	CcSEcCtD
Nedocromil—CYSLTR1—GPCR downstream signaling—EDN1—systemic scleroderma	0.000437	0.00157	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—ITGAM—systemic scleroderma	0.000436	0.00157	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—IRF8—systemic scleroderma	0.000436	0.00157	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CD247—systemic scleroderma	0.000436	0.00157	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—HSPG2—systemic scleroderma	0.000433	0.00156	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—EDN1—systemic scleroderma	0.000431	0.00155	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—CSK—systemic scleroderma	0.000428	0.00154	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—SMAD7—systemic scleroderma	0.000426	0.00153	CbGpPWpGaD
Nedocromil—Diarrhoea—Prednisone—systemic scleroderma	0.000422	0.000852	CcSEcCtD
Nedocromil—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000422	0.000851	CcSEcCtD
Nedocromil—CYSLTR1—Signaling Pathways—CSK—systemic scleroderma	0.000418	0.00151	CbGpPWpGaD
Nedocromil—Urticaria—Methotrexate—systemic scleroderma	0.00041	0.000826	CcSEcCtD
Nedocromil—HSP90AA1—Immune System—TNFAIP3—systemic scleroderma	0.000408	0.00147	CbGpPWpGaD
Nedocromil—Dizziness—Prednisone—systemic scleroderma	0.000408	0.000823	CcSEcCtD
Nedocromil—Body temperature increased—Methotrexate—systemic scleroderma	0.000408	0.000822	CcSEcCtD
Nedocromil—Abdominal pain—Methotrexate—systemic scleroderma	0.000408	0.000822	CcSEcCtD
Nedocromil—HSP90AA1—Immune System—BLK—systemic scleroderma	0.000404	0.00145	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—CD247—systemic scleroderma	0.000403	0.00145	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—EDN1—systemic scleroderma	0.000397	0.00143	CbGpPWpGaD
Nedocromil—Vomiting—Prednisone—systemic scleroderma	0.000392	0.000792	CcSEcCtD
Nedocromil—CYSLTR2—Signaling by GPCR—CCL2—systemic scleroderma	0.000391	0.00141	CbGpPWpGaD
Nedocromil—Rash—Prednisone—systemic scleroderma	0.000389	0.000785	CcSEcCtD
Nedocromil—Dermatitis—Prednisone—systemic scleroderma	0.000389	0.000784	CcSEcCtD
Nedocromil—Headache—Prednisone—systemic scleroderma	0.000387	0.00078	CcSEcCtD
Nedocromil—Hypersensitivity—Methotrexate—systemic scleroderma	0.00038	0.000767	CcSEcCtD
Nedocromil—HSP90AA1—Metabolism—HSPG2—systemic scleroderma	0.000371	0.00134	CbGpPWpGaD
Nedocromil—Asthenia—Methotrexate—systemic scleroderma	0.00037	0.000746	CcSEcCtD
Nedocromil—Nausea—Prednisone—systemic scleroderma	0.000367	0.000739	CcSEcCtD
Nedocromil—Diarrhoea—Methotrexate—systemic scleroderma	0.000353	0.000712	CcSEcCtD
Nedocromil—HSP90AA1—Axon guidance—MMP9—systemic scleroderma	0.000346	0.00125	CbGpPWpGaD
Nedocromil—Dizziness—Methotrexate—systemic scleroderma	0.000341	0.000688	CcSEcCtD
Nedocromil—CYSLTR2—Signaling Pathways—EDN1—systemic scleroderma	0.000338	0.00122	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CTLA4—systemic scleroderma	0.000331	0.00119	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—RHOB—systemic scleroderma	0.000329	0.00119	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—MMP2—systemic scleroderma	0.000329	0.00119	CbGpPWpGaD
Nedocromil—Vomiting—Methotrexate—systemic scleroderma	0.000328	0.000661	CcSEcCtD
Nedocromil—Rash—Methotrexate—systemic scleroderma	0.000325	0.000656	CcSEcCtD
Nedocromil—Dermatitis—Methotrexate—systemic scleroderma	0.000325	0.000655	CcSEcCtD
Nedocromil—Headache—Methotrexate—systemic scleroderma	0.000323	0.000652	CcSEcCtD
Nedocromil—HSP90AA1—Signaling Pathways—HSPG2—systemic scleroderma	0.000311	0.00112	CbGpPWpGaD
Nedocromil—Nausea—Methotrexate—systemic scleroderma	0.000306	0.000618	CcSEcCtD
Nedocromil—FPR1—Signaling Pathways—CCL2—systemic scleroderma	0.000305	0.0011	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CSK—systemic scleroderma	0.0003	0.00108	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—CCL2—systemic scleroderma	0.000294	0.00106	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—CTGF—systemic scleroderma	0.000282	0.00101	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—HLA-DQB1—systemic scleroderma	0.000272	0.000981	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—NOS3—systemic scleroderma	0.000272	0.000979	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—CCL2—systemic scleroderma	0.000271	0.000977	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—NOS3—systemic scleroderma	0.000262	0.000946	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—IL1A—systemic scleroderma	0.000259	0.000932	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CD40LG—systemic scleroderma	0.000257	0.000927	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—MMP9—systemic scleroderma	0.000247	0.000891	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—EDN1—systemic scleroderma	0.000234	0.000844	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CCL2—systemic scleroderma	0.000231	0.000833	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—MMP9—systemic scleroderma	0.000218	0.000786	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—MMP9—systemic scleroderma	0.000211	0.000759	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—NOS3—systemic scleroderma	0.000206	0.000742	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—TGFB1—systemic scleroderma	0.000204	0.000734	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—TGFB1—systemic scleroderma	0.00018	0.000648	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—TGFB1—systemic scleroderma	0.000174	0.000625	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—EDN1—systemic scleroderma	0.000168	0.000606	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—MMP9—systemic scleroderma	0.000165	0.000596	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CCL2—systemic scleroderma	0.00016	0.000577	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—NOS3—systemic scleroderma	0.000146	0.000527	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—NOS3—systemic scleroderma	0.000143	0.000514	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—TGFB1—systemic scleroderma	0.000136	0.000491	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—IL1B—systemic scleroderma	0.000135	0.000486	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—NOS3—systemic scleroderma	0.000123	0.000442	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CCL2—systemic scleroderma	0.000115	0.000414	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—MMP9—systemic scleroderma	0.000115	0.000413	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—NOS3—systemic scleroderma	0.000102	0.000369	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—TGFB1—systemic scleroderma	9.68e-05	0.000349	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—TGFB1—systemic scleroderma	9.44e-05	0.00034	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MMP9—systemic scleroderma	8.22e-05	0.000296	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—TGFB1—systemic scleroderma	6.78e-05	0.000244	CbGpPWpGaD
